Title: MMWR Vol. 58 / No. RR-3
| If you have trouble reading this e-mail, please click here.
|
|
|
Recommendations and Reports
Volume 58, No. RR-3
February 13, 2009
|
|
|
|
|
Plan to Combat Extensively
Drug-Resistant Tuberculosis
Recommendations of the Federal
Tuberculosis Task Force
|
|
|
|
|
Multidrug-resistant TB (MDR TB) is defined as TB that is resistant to the two most effective first-line therapeutic drugs, isoniazid and rifampin. Extensively drug-resistant (XDR) TB is defined as MDR TB that also is resistant to the most effective second-line therapeutic drugs used commonly
to treat MDR TB: fluoroquinolones and at least one of three injectable second-line drugs used to treat TB (amikacin, kanamycin, or capreomycin). XDR TB has been identified in all regions of the world, including the United States. Because of the limited responsiveness of XDR TB to available antibiotics, mortality rates among patients with XDR TB are similar to those of TB patients in the preantibiotic era. The recommendations provided in this report include specific action steps and new activities that will require additional funding and a renewed commitment by government and nongovernment organizations involved in domestic and international TB control efforts to be implemented effectively.
|
|
 full text
|
|
|
|
Department of Health and Human Services
Centers for Disease Control and Prevention
|
|
|
To change your subscriptions or preferences or stop subscriptions anytime, log in to your User Profile with your e-mail address. For questions or problems with the service, contact support@xxxxxxxxxxxxxxx.
This service is provided by CDC. Visit us on the web at www.cdc.gov.
Centers for Disease Control and Prevention (CDC) · 1600 Clifton Rd · Atlanta GA 30333 · 800-CDC-INFO (800-232-4636)
